Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

2 results
12:00 AM, Jun 20, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

PT001: Phase II started

Atrovent ipratropium HFA inhalation aerosol in about 100 patients. Boehringer Ingelheim GmbH (Ingelheim, Germany) markets Atrovent HFA
12:00 AM, Nov 22, 2004  |  BC Week In Review | Clinical News  |  Regulatory

Atrovent HFA regulatory update

FDA approved Atrovent HFA inhalation aerosol, a reformulation of Atrovent (CFC), for bronchospasm associated with chronic obstructive …
disease (COPD), including chronic bronchitis and emphysema. Boehringer Ingelheim Corp. , Ridgefield, Conn.   Product: Atrovent HFA